Laurant is a PharmD with a Master in Public Health Law and a Master in Business Administration. He has 30 years’ experience in the pharmaceutical and biotechnology industry though leading functions in international Regulatory/Pharmaceutical Affairs & Drug Development. His main areas of expertise include paediatric and orphan drug development.
As Chief Pharmaceutical Affairs Officer, Laurent Martin oversees the European regulatory activities though commercialisation of ORPHELIA Pharma’s paediatric and orphan medicinal products pipeline in oncology and neurology.
Prior to joining ORPHELIA Pharma, Laurent Martin spent 12 years at DBV Technologies. His last position in this biotechnology company being Chief Development Officer, fousing on the development of a new treatment for paediatric food allergies. Earlier, Laurent Martin also successfully managed the international registration of several paediatric orphan medicinal products of Orphan Europe now Recordati Rare Diseases in the metabolic diseases area.
